|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 9
Zeitschriftenartikel
Gligorov, Joseph; Pivot, Xavier; Ataseven, Beyhan; De Laurentiis, Michelino; Jung, Kyung Hae; Manikhas, Alexey; Azim, Hamdy Abdel; Gupta, Kushagra; Alexandrou, Ari; Herraez-Baranda, Luis; Tosti, Nadia und Restuccia, Eleonora
(2022):
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
In: Breast, Bd. 64: S. 151-158
Lu, Yen-Shen; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Cardoso, Fatima; Harbeck, Nadia; Hurvitz, Sara; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; De Laurentiis, Michelino; Im, Young-Hyuck; Kuemmel, Sherko; El-Saghir, Nagi; O'Regan, Ruth; Gasch, Claudia; Solovieff, Nadia; Wang, Craig; Wang, Yongyu; Chakravartty, Arunava; Ji, Yan und Tripathy, Debu
(2022):
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
In: Clinical Cancer Research, Bd. 28, Nr. 5: S. 851-859
Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock-Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Villanueva Vazquez, Rafael; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Lorenc, Karen Rodriguez; Babbar, Naveen; Tripathy, Debu und Lu, Yen-Shen
(2021):
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
In: Jco Precision Oncology, Bd. 5: S. 1408-1420
Mittendorf, Elizabeth A.; Zhang, Hong; Barrios, Carlos H.; Saji, Shigehira; Jung, Kyung Hae; Hegg, Roberto; Koehler, Andreas; Sohn, Joohyuk; Iwata, Hiroji; Telli, Melinda L.; Ferrario, Cristiano; Punie, Kevin; Penault-Llorca, Frederique; Patel, Shilpen; Anh Nguyen, Duc; Liste-Hermoso, Mario; Maiya, Vidya; Molinero, Luciana; Chui, Stephen Y. und Harbeck, Nadia
(2020):
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
In: Lancet, Bd. 396, Nr. 10257: S. 1090-1100
Hurvitz, Sara A.; Martin, Miguel; Jung, Kyung Hae; Huang, Chiun-Sheng; Harbeck, Nadia; Valero, Vicente; Stroyakovskiy, Daniil; Wildiers, Hans; Campone, Mario; Boileau, Jean-Francois; Fasching, Peter A.; Afenjar, Karen; Spera, Gonzalo; Lopez-Valverde, Vanesa; Song, Chunyan; Trask, Peter; Boulet, Thomas; Sparano, Joseph A.; Symmans, W. Fraser; Thompson, Alastair M. und Slamon, Dennis
(2019):
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
In: Journal of Clinical Oncology, Bd. 37, Nr. 25
Tripathy, Debu; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Harbeck, Nadia; Hurvitz, Sara A.; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; Laurentiis, Michelino de; Im, Young-Hyuck; Kümmel, Sherko; El-Saghir, Nagi; Liu, Mei-Ching; Carlson, Gary; Hughes, Gareth; Diaz-Padilla, Ivan; Germa, Caroline; Hirawat, Samit und Lu, Yen-Shen
(2018):
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 7: S. 904-915
Jung, Kyung Hae; Ataseven, Beyhan; Verrill, Mark; Pivot, Xavier; De Laurentiis, Michelino; Al-Sakaff, Nedal; Lauer, Sabine; Shing, Mona; Gligorov, Joseph und Azim, Hamdy A.
(2018):
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
In: Oncologist, Bd. 23, Nr. 10: S. 1137-1143
Hurvitz, Sara A.; Martin, Miguel; Symmans, W. Fraser; Jung, Kyung Hae; Huang, Chiun-Sheng; Thompson, Alastair M.; Harbeck, Nadia; Valero, Vicente; Stroyakovskiy, Daniil; Wildiers, Hans; Campone, Mario; Boileau, Jean-Francois; Beckmann, Matthias W.; Afenjar, Karen; Fresco, Rodrigo; Helms, Hans-Joachim; Xu, Jin; Lin, Yvonne G.; Sparano, Joseph und Slamon, Dennis
(2018):
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 1: S. 115-126
Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe und Piccart-Gebhart, Martine
(2016):
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 3: S. 357-366